Predictive potential of angiopoietin-2 in a mCRC subpopulation treated with vanucizumab in the McCAVE trial.

Front Oncol · 2023 · PMC10190963 · PMID 37207143

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Higher than median baseline levels of MKi67 and CA9 showed a trend towards a PFS benefit (upper 95% CI of the HR just over 1) in patients with wild-type KRAS treated with vanucizumab/mFOLFOX-6 versus bevacizumab/mFOLFOX-6.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.